Aspergillus flavus Infections in Children With Leukemia Despite Liposomal Amphotericin-B Prophylaxis

Nadja Hawwa Vissing; Birgitte Lausen; Marianne Hutchings Hoffmann; Bodil Als-Nielsen; Kjeld Schmiegelow; Jannik Helweg-Larsen; Maiken Cavling Arendrup; Ulrikka Nygaard

doi:10.1097/INF.0000000000003189

Aspergillus flavus Infections in Children With Leukemia Despite Liposomal Amphotericin-B Prophylaxis

Nadja Hawwa Vissing, Birgitte Lausen, Marianne Hutchings Hoffmann, Bodil Als-Nielsen, Kjeld Schmiegelow, Jannik Helweg-Larsen, Maiken Cavling Arendrup, Ulrikka Nygaard

4 Citations (Scopus)

Abstract

Liposomal amphotericin-B (L-AmB) prophylaxis is used in children with leukemia when azoles are contraindicated, but its effect is debated. We reviewed cases of invasive aspergillosis despite L-AmB 2.5 mg/kg twice weekly in children with high-risk leukemia during 2012-2019. Ten (16%) of 62 children had proven or probable aspergillosis. Thus, L-AmB prophylaxis offered insufficient protection for Aspergillus, in particular for Aspergillus flavus.

Original language	English
Journal	The Pediatric infectious disease journal
Volume	40
Issue number	8
Pages (from-to)	749-752
Number of pages	4
ISSN	0891-3668
DOIs	https://doi.org/10.1097/INF.0000000000003189
Publication status	Published - 1 Aug 2021

Keywords

Adolescent
Amphotericin B/therapeutic use
Antifungal Agents/therapeutic use
Aspergillosis/prevention & control
Aspergillus flavus/drug effects
Child
Child, Preschool
Denmark/epidemiology
Hospitals, Pediatric
Humans
Infant
Leukemia/complications
Retrospective Studies
invasive fungal disease
Aspergillus flavus
prophylaxis
pediatric leukemia

Access to Document

10.1097/INF.0000000000003189

Cite this

@article{bfa080d783d84922904287fa1c29dbed,

title = "Aspergillus flavus Infections in Children With Leukemia Despite Liposomal Amphotericin-B Prophylaxis",

abstract = "Liposomal amphotericin-B (L-AmB) prophylaxis is used in children with leukemia when azoles are contraindicated, but its effect is debated. We reviewed cases of invasive aspergillosis despite L-AmB 2.5 mg/kg twice weekly in children with high-risk leukemia during 2012-2019. Ten (16%) of 62 children had proven or probable aspergillosis. Thus, L-AmB prophylaxis offered insufficient protection for Aspergillus, in particular for Aspergillus flavus.",

keywords = "Adolescent, Amphotericin B/therapeutic use, Antifungal Agents/therapeutic use, Aspergillosis/prevention & control, Aspergillus flavus/drug effects, Child, Child, Preschool, Denmark/epidemiology, Hospitals, Pediatric, Humans, Infant, Leukemia/complications, Retrospective Studies, invasive fungal disease, Aspergillus flavus, prophylaxis, pediatric leukemia",

author = "Vissing, {Nadja Hawwa} and Birgitte Lausen and {Hutchings Hoffmann}, Marianne and Bodil Als-Nielsen and Kjeld Schmiegelow and Jannik Helweg-Larsen and Arendrup, {Maiken Cavling} and Ulrikka Nygaard",

year = "2021",

month = aug,

day = "1",

doi = "10.1097/INF.0000000000003189",

language = "English",

volume = "40",

pages = "749--752",

journal = "The Pediatric infectious disease journal",

issn = "0891-3668",

publisher = "Lippincott Williams and Wilkins",

number = "8",

}

TY - JOUR

T1 - Aspergillus flavus Infections in Children With Leukemia Despite Liposomal Amphotericin-B Prophylaxis

AU - Vissing, Nadja Hawwa

AU - Lausen, Birgitte

AU - Hutchings Hoffmann, Marianne

AU - Als-Nielsen, Bodil

AU - Schmiegelow, Kjeld

AU - Helweg-Larsen, Jannik

AU - Arendrup, Maiken Cavling

AU - Nygaard, Ulrikka

PY - 2021/8/1

Y1 - 2021/8/1

N2 - Liposomal amphotericin-B (L-AmB) prophylaxis is used in children with leukemia when azoles are contraindicated, but its effect is debated. We reviewed cases of invasive aspergillosis despite L-AmB 2.5 mg/kg twice weekly in children with high-risk leukemia during 2012-2019. Ten (16%) of 62 children had proven or probable aspergillosis. Thus, L-AmB prophylaxis offered insufficient protection for Aspergillus, in particular for Aspergillus flavus.

AB - Liposomal amphotericin-B (L-AmB) prophylaxis is used in children with leukemia when azoles are contraindicated, but its effect is debated. We reviewed cases of invasive aspergillosis despite L-AmB 2.5 mg/kg twice weekly in children with high-risk leukemia during 2012-2019. Ten (16%) of 62 children had proven or probable aspergillosis. Thus, L-AmB prophylaxis offered insufficient protection for Aspergillus, in particular for Aspergillus flavus.

KW - Adolescent

KW - Amphotericin B/therapeutic use

KW - Antifungal Agents/therapeutic use

KW - Aspergillosis/prevention & control

KW - Aspergillus flavus/drug effects

KW - Child

KW - Child, Preschool

KW - Denmark/epidemiology

KW - Hospitals, Pediatric

KW - Humans

KW - Infant

KW - Leukemia/complications

KW - Retrospective Studies

KW - invasive fungal disease

KW - Aspergillus flavus

KW - prophylaxis

KW - pediatric leukemia

UR - http://www.scopus.com/inward/record.url?scp=85110574413&partnerID=8YFLogxK

U2 - 10.1097/INF.0000000000003189

DO - 10.1097/INF.0000000000003189

M3 - Journal article

C2 - 34250973

SN - 0891-3668

VL - 40

SP - 749

EP - 752

JO - The Pediatric infectious disease journal

JF - The Pediatric infectious disease journal

IS - 8

ER -

Aspergillus flavus Infections in Children With Leukemia Despite Liposomal Amphotericin-B Prophylaxis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this